Back to Tesamorelin
Tesamorelin Dosage Guide
Complete dosing protocol, reconstitution steps, and interactive calculator for Tesamorelin.
Dosing & Reconstitution Guide
The FDA-approved dose is 2 mg subcutaneously once daily for HIV-related lipodystrophy. All other uses remain investigational and are not FDA-approved.
Standard / Gradual Approach
20mg VialstandardPhaseDoseVolume
Week 11 mg / 1000 mcg15 units (0.15 mL)
Weeks 2–12+2 mg / 2000 mcg30 units (0.30 mL)
Standard / Gradual Approach
10mg VialstandardPhaseDoseVolume
Week 11 mg / 1000 mcg30 units (0.30 mL)
Weeks 2–12+2 mg / 2000 mcg60 units (0.60 mL)
Standard / Gradual Approach
5mg VialstandardPhaseDoseVolume
Week 11 mg / 1000 mcg50 units (0.50 mL)
Weeks 2–12+2 mg / 2000 mcg100 units (1.00 mL)
Protocol Summary
Subcutaneous (SQ): daily · Dose range 2–2 mg with gradual titration
Cycle Length: 4–8 weeks typical; reassess before extending
Frequency & Cycling
SubQ Injection
Administer 2 mg SubQ once daily for up to 60 days. Typical off-label use includes 4–6 weeks on, followed by a 2–4 week break. Can be combined with Ipamorelin or CJC-1295 for amplified GH response. Monitor IGF-1 levels and glucose tolerance during extended use.
🧪 Quick Start
Vial Size
10 mg
BAC Water
3 mL
Concentration
3300 mcg/unit
Starting Dose
1 mg / 1000 mcg (15 units (0.15 mL))
Maintenance Dose
2 mg / 2000 mcg (30 units (0.30 mL))
🧮 Dose Calculator
Concentration
33.3
mcg/unit
Draw Volume
15
units (0.150 mL)
For a 500 mcg dose, draw 15 units on a U-100 insulin syringe